

Method of Treatment to prevent or reverse age-associated inflammation, cognitive decline, and neurodegeneration

Aging is one of the leading causes that is associated with brain dysfunction, degeneration, and disease. Progressive inflammation in the brain due to age adversely affects brain function and increases susceptibility to neurodegenerative diseases like Alzheimer's disease. The Andreasson lab has invented a novel method to target age-associated neurological diseases. By interfering with inflammatory prostaglandin signaling pathways, the invention reverses age-associated inflammation and age-associated cognitive decline. This method reverses systemic and brain inflammation associated with aging and is associated with a restoration of hippocampal function and memory to a youthful phenotype in preclinical studies. The invention can be used to address the critical problem of age-associated inflammation, cognitive decline, and neurodegeneration.

Applications

- Target and treat age-associated neurological diseases, such as Alzheimer's
- Reversal and/or prevention of inflammation-driven musculo-skeletal degeneration, renal diseases, and cancer

Advantages

- Anti-aging agent to prevent brain aging and degeneration
- Non-toxic and biologically compatible

Publications

- Minhas, P. S., Latif-Hernandez, A., McReynolds, M. R., Durairaj, A. S., Wang, Q., Rubin, A., ... & Andreasson, K. I. (2021). "[Restoring metabolism of myeloid cells reverses cognitive decline in ageing](#)". Nature, 590(7844), 122-128.

Patents

- Published Application: [20220048987](#)

Innovators

- Katrin Andreasson
- Paras Minhas
- Philip Beachy

Licensing Contact

Hyunjin Kim

Licensing Manager, Life Sciences

[Email](#)